-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Peak Bio (NASDAQ:PKBO) Stock Price Up 36.8%
Peak Bio (NASDAQ:PKBO) Stock Price Up 36.8%
Peak Bio, Inc. (NASDAQ:PKBO – Get Rating)'s stock price rose 36.8% during mid-day trading on Friday . The company traded as high as $7.59 and last traded at $6.50. Approximately 529,309 shares traded hands during trading, an increase of 172% from the average daily volume of 194,357 shares. The stock had previously closed at $4.75.
Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH began coverage on Peak Bio in a research note on Friday, November 4th. They set a "buy" rating and a $15.00 price objective on the stock.
Peak Bio Stock Up 36.8 %
Peak Bio Company Profile
(Get Rating)
Peak Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
See Also
- Get a free copy of the StockNews.com research report on Peak Bio (PKBO)
- MarketBeat: Week in Review 11/21 – 11/25
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.
Peak Bio, Inc. (NASDAQ:PKBO – Get Rating)'s stock price rose 36.8% during mid-day trading on Friday . The company traded as high as $7.59 and last traded at $6.50. Approximately 529,309 shares traded hands during trading, an increase of 172% from the average daily volume of 194,357 shares. The stock had previously closed at $4.75.
Peak Bio, Inc.（纳斯达克股票代码：PKBO — Get Rating）的股价在周五午盘交易中上涨了36.8％。该公司的交易价格高达7.59美元，最后一次交易价格为6.50美元。交易期间约有529,309股股票交易，较平均每日交易量194,357股增长了172％。该股此前收于4.75美元。
Wall Street Analyst Weigh In
华尔街分析师权衡一下
Separately, LADENBURG THALM/SH SH began coverage on Peak Bio in a research note on Friday, November 4th. They set a "buy" rating and a $15.00 price objective on the stock.
另外，LADENBURG THALM/SH SH于11月4日星期五在一份研究报告中开始对Peak Bio进行报道。他们为该股设定了 “买入” 评级和15.00美元的价格目标。
Peak Bio Stock Up 36.8 %
Peak Bio股票上涨36.8％
Peak Bio Company Profile
Peak Bio 公司简介
(Get Rating)
（获取评分）
Peak Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
Peak Bio, Inc是一家临床阶段的生物制药公司，专注于开发治疗药物，以解决肿瘤学和炎症领域未满足的需求。该公司的专有毒素PH-1或Thailanstatin（一种剪接体调节剂）正被用来生产其首批新的ADC候选产品，以满足癌症患者未得到满足的需求。
See Also
另见
- Get a free copy of the StockNews.com research report on Peak Bio (PKBO)
- MarketBeat: Week in Review 11/21 – 11/25
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- 免费获取 StockNews.com 关于 Peak Bio (PKBO) 的研究报告
- MarketBeat：本周回顾 11/21 — 11/25
- 三只CBD股票将在新兴行业中占据主导地位
- 60/40 的投资组合还在流行吗？
- 微软股票：是时候备份卡车了吗？
- Salesforce裁员，尽管面临挑战，但收入仍表现强劲
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.
接收Peak Bio Daily的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Peak Bio及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧